Biotech Values

[mcbio]

Of note NVAX pulled in a few ex-Medimmune people (ex-Synagis).

NVAX just reeled in another ex-Medimmune employee (http://www.novavax.com/download/releases/2011-03-11%20Erica%20Shane%20Appointment%20Announcement%20Final.pdf ). Also, just listened to today's CC, and management made reference to expecting to land a partner in the next year or so on the RSV vaccine as there was reference to partnering deals taking time. They did state that they have received partnering interest from the usual potential partners since the Phase 1 RSV vaccine data was released.

NVAX also guided for about a year or so of available cash, and that was taking into account future at-the-market offerings, so there may be a bit of crunch between available cash and needing to land a partner without some significant dilution, but I'll be surprised if NVAX doesn't find a partner for the RSV vaccine.